Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 03, 2024 11:46pm
141 Views
Post# 36344402

RE:Grant of rights

RE:Grant of rightsI would say a grant of 64,000 rights for the CEO, is a good sign.
recall, Dec 2919.
I will never forget that time. I was in local hospital E.R. Waiting to be seen. Every time I checked my phone , the S.P. Was up substantially.
There was a larger  than normal short holding, The S.P. Was hurting bad, even a delisting notice.
Sound familiar?
short squeeze.coupled with some solid N.R.
Huge volume, lots of followings etc etc.
Sadley, Many other things came along & derailed the expected partnership.
Now, 5 years later, can this time be better?
back then they had only MBc.
Now add on pancreatic & the whole Gobblet scene.
And, upcoming presentation for -3 MBc alongside Incyte.
With a sprinkle of CAR- T, 
much further along than Dec of 2019.
That is why there will not be a R/S January or ever.
Staytuned.

BTW , little has been said about Dr. Matt, I do wish him well.
He discovered Pelareorep. Wrote a thesis leading to various patents.
He has a personal interst in seeing Pela sucseed. 
One way or the other we are in for a very exciting & interesting next 3 months.




<< Previous
Bullboard Posts
Next >>